Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells $116,606.70 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 4,683 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $24.90, for a total transaction of $116,606.70. Following the completion of the transaction, the chief financial officer owned 110,342 shares in the company, valued at $2,747,515.80. This represents a 4.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Howard Horn also recently made the following trade(s):

• On Wednesday, April 1st, Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $20.97, for a total transaction of $98,202.51.
• On Tuesday, March 3rd, Howard Horn sold 1,635 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $22.40, for a total value of $36,624.00.
• On Monday, March 2nd, Howard Horn sold 8,409 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $22.70, for a total value of $190,884.30.

Ultragenyx Pharmaceutical Trading Up 3.7%

Shares of RARE opened at $25.93 on Thursday. The stock has a market cap of $2.55 billion, a P/E ratio of -4.24 and a beta of 0.39. The stock’s 50-day moving average price is $22.61 and its two-hundred day moving average price is $26.84. Ultragenyx Pharmaceutical Inc. has a 1 year low of $18.29 and a 1 year high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.50) by ($0.34). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 2,272.48%. The firm had revenue of $136.00 million for the quarter, compared to analyst estimates of $158.38 million. During the same quarter in the prior year, the firm posted ($1.57) EPS. The firm’s revenue for the quarter was down 2.2% compared to the same quarter last year. As a group, equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.49 EPS for the current year.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Wells Fargo raised its price target to $47 and maintained an “overweight” rating, signaling bullish analyst support that can boost investor sentiment. Wells Fargo Price Target
• Positive Sentiment: Management will participate in a Bank of America Healthcare Conference fireside on May 12 (CFO Howard Horn and VP of IR Joshua Higa). Increased investor access and management commentary can help re?price uncertainty from the quarter. Conference Announcement
• Neutral Sentiment: The company set FY?2026 revenue guidance of $730M–$760M (vs. consensus ~$747M). The range straddles Street estimates, which may be seen as mixed but not a major surprise. Q1 Results & Guidance
• Neutral Sentiment: Coverage noise from similarly named companies: Barron’s noted a new “Rare” IPO (Rare Earth Americas). This can create ticker/name confusion for some retail flows but is not company?specific. Barron’s IPO Note
• Negative Sentiment: Q1 earnings missed expectations: EPS of ($1.84) vs. consensus (~$1.50 loss) and revenue $136M vs. est. $158M. Crysvita sales fell seasonally; growth in Evkeeza and Dojolvi only partially offset the decline — this weakened near?term fundamentals. Earnings Release/Details
• Negative Sentiment: Insider sales disclosed: CFO Howard Horn sold 4,683 shares (May 1) and EVP Eric Crombez sold 344 shares (May 5) — the latter explicitly to cover tax withholding on equity vesting. While management says these are tax/vesting?related, multiple insider sales can be interpreted negatively by some investors. Insider Filing (Crombez)
• Negative Sentiment: Some sell/neutral analyst moves (e.g., Wedbush cut its price target to $26 and set a “neutral” rating) add offsetting downward pressure versus the Wells Fargo upgrade. Analyst Note (Wedbush)

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several institutional investors have recently bought and sold shares of RARE. Vanguard Group Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company’s stock worth $236,068,000 after acquiring an additional 131,087 shares in the last quarter. State Street Corp boosted its holdings in Ultragenyx Pharmaceutical by 16.5% during the fourth quarter. State Street Corp now owns 4,303,046 shares of the biopharmaceutical company’s stock worth $98,970,000 after purchasing an additional 610,559 shares during the last quarter. Wellington Management Group LLP grew its position in Ultragenyx Pharmaceutical by 26.6% in the fourth quarter. Wellington Management Group LLP now owns 2,461,910 shares of the biopharmaceutical company’s stock valued at $56,624,000 after purchasing an additional 516,781 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Ultragenyx Pharmaceutical by 1,030.4% in the first quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock valued at $47,298,000 after purchasing an additional 2,057,951 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in Ultragenyx Pharmaceutical by 614.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after buying an additional 1,864,164 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Wall Street Analyst Weigh In

RARE has been the subject of a number of research analyst reports. Barclays decreased their target price on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, April 29th. JPMorgan Chase & Co. decreased their price objective on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a research report on Thursday, March 12th. Truist Financial raised Ultragenyx Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, March 25th. Morgan Stanley lifted their price target on shares of Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, April 16th. Finally, Wedbush reduced their price target on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $60.94.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.